Wells Fargo’s Whitehawk Therapeutics WHWK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$31.8K Sell
8,469
-18,705
-69% -$78.8K ﹤0.01% 5729
2026
Q2
$124K Buy
+27,174
New +$113K ﹤0.01% 5444
2025
Q2
– Sell
-33
Closed -$59 – 7442
2025
Q1
$59 Sell
33
-567
-95% -$1.48K ﹤0.01% 6428
2024
Q4
$1.89K Sell
600
-2,222
-79% -$5.03K ﹤0.01% 6195
2024
Q3
$5.81K Sell
2,822
-200
-7% -$323 ﹤0.01% 5898
2024
Q2
$4.41K Sell
3,022
-6,769
-69% -$12.5K ﹤0.01% 5892
2024
Q1
$22.9K Buy
9,791
+737
+8% +$1.42K ﹤0.01% 5543
2023
Q4
$18.3K Buy
9,054
+723
+9% +$3.03K ﹤0.01% 5668
2023
Q3
$40.3K Sell
8,331
-1,983
-19% -$11.5K ﹤0.01% 5293
2023
Q2
$70.5K Buy
10,314
+5,592
+118% +$43.5K ﹤0.01% 5242
2023
Q1
$34.2K Buy
4,722
+3,156
+202% +$33.7K ﹤0.01% 5376
2022
Q4
$20.1K Sell
1,566
-158
-9% -$2.06K ﹤0.01% 5259
2022
Q3
$25K Sell
1,724
-365
-17% -$4.8K ﹤0.01% 5297
2022
Q2
$26K Buy
2,089
+997
+91% +$14.8K ﹤0.01% 5326
2022
Q1
$18K Buy
1,092
+298
+38% +$5.71K ﹤0.01% 6058
2021
Q4
$19K Buy
794
+714
+893% +$17.9K ﹤0.01% 6350
2021
Q3
$2K Sell
80
-1
-1% -$30 ﹤0.01% 6603
2021
Q2
$2K Hold
81
– – ﹤0.01% 6571
2021
Q1
$1K Hold
81
– – ﹤0.01% 6783
2020
Q4
$1K Buy
81
+33
+69% +$706 ﹤0.01% 6392
2020
Q3
$1K Buy
48
+2
+4% +$42 ﹤0.01% 6244
2020
Q2
$1K Buy
46
+36
+360% +$471 ﹤0.01% 6199
2020
Q1
$0 Buy
+10
New +$92 ﹤0.01% 6941

Other funds holding WHWK

Wells Fargo's WHWK Position: Q3 2026 in Review

Wells Fargo reduced its Whitehawk Therapeutics (WHWK) stake by 69% in Q3 2026, selling an estimated $78.8K and leaving 8,469 shares worth $31.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5729.

Wells Fargo first reported a position in WHWK in Q1 2020 and has held it in 23 quarters since. The position peaked at $124K in Q2 2026. 91 funds tracked by Wall St. Rank hold WHWK as of Q3 2026.

  • Wells Fargo held 8,469 shares of Whitehawk Therapeutics worth $31.8K as of Q3 2026.
  • Wells Fargo sold 18,705 Whitehawk Therapeutics shares in Q3 2026, an estimated $78.8K.
  • Whitehawk Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #5729 holding.
  • Wells Fargo first reported a position in Whitehawk Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Wells Fargo's Whitehawk Therapeutics position peaked at $124K in Q2 2026.
  • 91 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2026.

Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.